机构:[1]Nanjing Key Laboratory of Pediatrics, Children’s Hospital of Nanjing Medical University, Nanjing, China[2]Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China[3]Department of Nephrology, Children’s Hospital of Nanjing Medical University, Nanjing, China[4]Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China[5]Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China医技科室医学影像科首都医科大学附属安贞医院
Ureteral obstruction is associated with reduced expressions of renal sodium transporters, which contributes to impaired urinary concentrating capacity. In this study, we employed a synthetic mitochondrial superoxide dismutase 2 (SOD2) mimic MnTBAP to investigate the role of mitochondrial oxidative stress in modulating the sodium transporters in obstructive kidney disease. Following unilateral ureteral obstruction (UUO) for 7 days, a global reduction of sodium transporters including NHE3, NCC, NKCC2, and ENaC alpha was observed as determined by qRT-PCR, Western Blotting or immunohistochemistry. Among these sodium transporters, the downregulation of NHE3, NCC, and NKCC2 was partially reversed by MnTBAP treatment. In contrast, the reduction of ENaC alpha was not affected by MnTBAP. The beta and. subunits of ENaC were not significantly altered by ureteral obstruction or MnTBAP therapy. To further confirm the anti-oxidant effect of MnTBAP, we examined the levels of TBARs in the urine collected from the obstructed ureters of UUO mice and bladder of sham mice. As expected, the increment of urinary TBARs in UUO mice was entirely abolished by MnTBAP therapy, indicating an amelioration of oxidative stress. Meantime, we found that three types of SOD were all reduced in obstructed kidneys determined by qRT-PCR, which was unaffected by MnTBAP. Collectively, these results demonstrated an important role of mitochondrial oxidative stress in mediating the downregulation of sodium transporters in obstructive kidney disease.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81370802, 81300591, 81670647, 81600557, 81770690, 81570616]; National Key Research and Development Program [2016YFC0906103]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK2012001]
第一作者机构:[1]Nanjing Key Laboratory of Pediatrics, Children’s Hospital of Nanjing Medical University, Nanjing, China[2]Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
通讯作者:
通讯机构:[1]Nanjing Key Laboratory of Pediatrics, Children’s Hospital of Nanjing Medical University, Nanjing, China[3]Department of Nephrology, Children’s Hospital of Nanjing Medical University, Nanjing, China
推荐引用方式(GB/T 7714):
Liu Mi,Zhu Yangyang,Sun Ying,et al.MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease[J].ONCOTARGET.2018,9(1):394-403.doi:10.18632/oncotarget.23037.
APA:
Liu, Mi,Zhu, Yangyang,Sun, Ying,Wen, Zhaoying,Huang, Songming...&Zhang, Yue.(2018).MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease.ONCOTARGET,9,(1)
MLA:
Liu, Mi,et al."MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease".ONCOTARGET 9..1(2018):394-403